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Introduction 
Before the identification of McLeod neuroacanthocytosis syndrome (MLS) and chorea-
acanthocytosis (ChAc) as genetically distinct disorders, these two disorders, which have 
remarkable clinical similarities, were confusinglylumped together under the term 
‘‘neuroacanthocytosis.’’ Genetic diagnosis has enabled us to identify features that 
initially appeared to be specific to each of the disorders. However, with increased 
availability of genetic and proteinbased testing, it has become apparent that certain 
phenotypic features thought to be specific to one disorder may indeed be found in the 
other, such as feeding dystonia1 and head drops.2 Here we provide video documentation 
of a case of MLS that evolved from chorea to parkinsonism, a disease course that has 
not previously been reported on, and that is more typical of ChAc.3 
MLS is an X-linked disorder with central nervous system (CNS) features similar 
to Huntington’s disease (HD).3,4 MLS is caused by mutations in the XK gene encoding 
for the XK protein, which presents the Kx blood-group antigen on red blood cells 
(RBCs).3–5 The CNS manifestations of MLS usuallystart in the fourth or fifth decades 
and comprise chorea, psychiatric symptoms, cognitive decline, and tonic-clonic 
seizures.3–5 Neuromuscular manifestations include axonal sensorimotor neuropathy, 
neurogenic muscle atrophy, and myopathy.3–5 Hepatosplenomegaly and cardiomyopathy 
are typical.3–5 Diagnosis of MLS is indicated by the HD-like features, additional 
neuromuscular manifestations, in particular, absent or diminished deep tendon reflexes, 
and the laboratory findings of elevated creatine kinase (CK) levels, RBC 
acanthocytosis, and the presence of the McLeod blood-group phenotype. 
Neuroradiological studies demonstrate progressive striatal atrophy.   
 
Case report    
The patient was a chemical engineer, the elder of two brothers affected with MLS, as 
previously described.6 He presented at age 56 and reported a 9-year history of a chorea 
associated with episodic major depression. He noted reduced ability to concentrate at 
work and diminished ability to control his emotions in everyday life. In addition, he 
showed obsessive-compulsive symptoms, such as checking and ordering in symmetry 
and exactness. Upon first neurological examination, he was alert and fully oriented. 
Cognitive testing demonstrated a mild impairment. He had generalized chorea, tic-like 
grimacing, shoulder shrugging, and sniffing (see Video, Segment 1, 2 years after 
presentation). Blood examination after dilution with heparinized isotonic 
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saline demonstrated 29% acanthocytes. Cerebral MRI showed marked caudate atrophy. 
Molecular genetic analysis of the XK gene demonstrated a 5-bp (base-pair) deletion in 
exon 2 of the XK gene (c. 938-942delCTCTA).6  
After 8 years, he developed marked progressive parkinsonian features with a 
masked facies and reduced blinking, frontalis contraction similar to that observed in 
progressive supranuclear palsy, hypophonic and monotonous speech, rigidity, 
and generalized bradykinesia (see Video, Segment 2). The patient is wheelchair bound 
as the result of myopathy.7 He had not received dopamine (DA) D2-receptor 
blocking drugs. Parkinsonian symptoms responded only partially to levodopa in doses 
up to 1 g daily. 99mTc-TRODAT- 1 single-photon emision computed tomography 
(SPECT) scan showed a marked decrease in putamen DA transporter binding, 
consistent with loss of nigrostriatal neurons (Fig. 1). 
 
Discussion 
Both MLS and ChAc may present with a variety of movement disorders in the same 
patient during the course of the disease. Hyperkinetic features may be attributed to loss 
of striatal projection neurons, presumably enkephalinergic neurons, which comprise the 
indirect pathway, as in early HD.8 Akinetic-rigid features may be the result of 
striatonigral degeneration, with loss of striatal projection neurons of the direct pathway, 
comparable to advanced HD, and, as suggested in this case, by a minimal response to L-
dopa. As demonstrated by the SPECT data, loss of nigrostriatal dopaminergic neurons 
may also play a role. The neuropathology of MLS typically involves, predominantly, 
the caudate nucleus and putamen, but not the SN.9 It is more common for patients with 
ChAc to show a progression from a hyperkinetic syndrome with chorea and tics to 
parkinsonism and dystonia. Correspondingly, the neuropathology of ChAc is more 
extensive,10 involving the SN, globus pallidus, and thalamus, in addition to primarily 
affecting the caudate nucleus and putamen. Thus, even though, with genetic advances, 
MLS and ChAc have diverged from being covered by the umbrella term of 
neuroacanthocytosis, it may be that they are ultimately more similar and, possibly, may 
share a common underlying pathophysiology, with MLS being the result of the same 
process at the cellular level as ChAc, but with later onset. 
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Legends to the video 
Segment 1. The patient presented with generalized chorea, shoulder shrugging, and 
sniffing. Segment 2. The patient now has a masked facies with reduced blinking, 
hypophonic and monotonous speech, and generalized bradykinesia.   
 
Figure 1 
99mTc-TRODAT-1  SPECT. The Mc Leod patient (A and B) shows marked loss of 
putaminal dopamine transporter binding in comparison to a normal subject (C). 
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